The efficacy of anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapies is correlative to the levels of expression of CTLA-4, CD80/86, PD-1, and PD-L1 in the patients’ tumor cells, APCs, and T cells (Figure 3). The gene discussed is CD274; the disease is neoplasm.